Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | EDNRB | P24530 | 1/20 | 0.39 |
| ▸ | EDNRA | P25101 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | GLS | O94925 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2955165 | 0.74 | AR (0.36) | S100A4ADORA3ARHSD11B1AKR1C3 | |
| SCHEMBL30991817 | 0.74 | AR (0.36) | S100A4ADORA3ARHSD11B1AKR1C3 | |
| SCHEMBL12405330 | 0.74 | S100A4 (0.47) | S100A4ADORA3ARHSD11B1AKR1C3 | |
| SCHEMBL8364609 | 0.73 | POLB (0.35) | EDNRBEDNRACYP19A1ALDH1A1MAPT | |
| SCHEMBL30737888 | 0.72 | AR (0.46) | S100A4ADORA3ARHSD11B1AKR1C3 | |
| SCHEMBL19302757 | 0.72 | AR (0.46) | S100A4ADORA3ARHSD11B1AKR1C3 | |
| SCHEMBL11869980 | 0.72 | AR (0.46) | S100A4ADORA3ARHSD11B1AKR1C3 | |
| SCHEMBL2929675 | 0.72 | AR (0.46) | S100A4ADORA3ARHSD11B1AKR1C3 | |
| SCHEMBL5536280 | 0.72 | S100A4 (0.45) | S100A4ADORA3ARHSD11B1AKR1C3 | |
| SCHEMBL12719040 | 0.72 | KDM1A (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120116027-A1 | PROCESS FOR THE PURIFICATION OF HUMAN GROWTH HORMONE POLYPEPTIDES USING AFFINITY RESINS COMPRISING SPECIFIC LIGANDS | NOVO NORDISK A/S (DK) | 2012-05-10 | — | — | US | disclosed |
| EP-2356141-A1 | PROCESS FOR THE PURIFICATION OF HUMAN GROWTH HORMONE POLYPEPTIDES USING AFFINITY RESINS COMPRISING SPECIFIC LIGANDS | Novo Nordisk A/S (DK) | 2011-08-17 | — | — | EP | disclosed |
| EP-1537116-B1 | PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |
| WO-2010055135-A1 | PROCESS FOR THE PURIFICATION OF HUMAN GROWTH HORMONE POLYPEPTIDES USING AFFINITY RESINS COMPRISING SPECIFIC LIGANDS | NOVO NORDISK A/S (DK) | 2010-05-20 | — | — | WO | disclosed |
| US-6699909-B1 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS; CENTRAL NERVOUS SYSTEM DISORDERS | PRESCIENT NEUROPHARMA INC. (CA) | 2004-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116027-A1 | PROCESS FOR THE PURIFICATION OF HUMAN GROWTH HORMONE POLYPEPTIDES USING AFFINITY RESINS COMPRISING SPECIFIC LIGANDS | GHRHR, GHITM, GHSR | S100A4 1647/4885ADORA3 4066/4885AR 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.